In addition, a selective vasopressin V2 receptor antagonist (Samsca®) was approved in Japan in 2014 as the first drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD). The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.